title: Immunogenicity of hepatitis a vaccine in children with cancer.
abstract: This study evaluated the immuned response of the hepatitis A vaccine in children with cancer who were receiving chemotherapy. Twenty-eight patients with lymphomas or solid tumors and who had negative serology for hepatitis A were enrolled. The median age was 4.7 years (range 2-16). The patients received 1440 IU hepatitis A vaccine at 0 and 6 months. Seroconversion rates at the first and seventh months were 60% (n = 17/28 patients) and 89% (n = 24/27 patients). No adverse effects were observed. The hepatitis A vaccine was found to be effective and safe in children with cancer.
authors.affiliation: Department of Pediatric Oncology, Hacettepe University, Institute of Oncology, 06100, Ankara, Turkey. yavuzkoksal@yahoo.com
authors.forename: Yavuz
authors.initials: Y
authors.lastname: Köksal
authors.forename: Bilgehan
authors.initials: B
authors.lastname: Yalçin
authors.forename: G Burça
authors.initials: GB
authors.lastname: Aydin
authors.forename: Neriman
authors.initials: N
authors.lastname: Sari
authors.forename: Nalan
authors.initials: N
authors.lastname: Yazici
authors.forename: Ali
authors.initials: A
authors.lastname: Varan
authors.forename: Tezer
authors.initials: T
authors.lastname: Kutluk
authors.forename: Canan
authors.initials: C
authors.lastname: Akyüz
authors.forename: Münevver
authors.initials: M
authors.lastname: Büyükpamukçu
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D035922:Hepatitis A Antibodies / Q000096:biosynthesis / Q000097:blood*; D022362:Hepatitis A Vaccines / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000096:biosynthesis / Q000097:blood; D007075:Immunoglobulin M / Q000096:biosynthesis / Q000097:blood; D008297:Male; D009369:Neoplasms / Q000276:immunology*; D011446:Prospective Studies
chemical_list: D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D007074:Immunoglobulin G; D007075:Immunoglobulin M